Testosterone undecanoate explained

Verifiedfields:verified
Watchedfields:verified
Verifiedrevid:470603074
Width:250
Width2:250
Tradename:Oral: Kyzatrex, Andriol, Jatenzo, Testoheal, others
IM: Aveed, Nebido, others
Dailymedid:Testosterone_undecanoate
Pregnancy Au:D
Pregnancy Au Comment:[1]
Addiction Liability:Moderate [2]
Routes Of Administration:By mouth, intramuscular injection
Class:Androgen
Anabolic steroid; Androgen ester
Atc Prefix:G03
Atc Suffix:BA03
Legal Ca:Schedule IV
Legal Us:Schedule III
Legal Us Comment:[3]
Legal Status:Rx-only
Dependency Liability:Moderate [4]
Bioavailability:Oral

3–7%
Intramuscular: high

Protein Bound:High (testosterone)
Metabolism:Liver
Metabolites:Testosterone, undecanoic acid, metabolites of testosterone
Elimination Half-Life: (in tea seed oil): 20.9 days[5]
(in castor oil): 33.9 days
Excretion:~90% Urine, 6% feces
Cas Number:5949-44-0
Pubchem:65157
Drugbank:DB13946
Chemspiderid:58664
Unii:H16A5VCT9C
Kegg:D06087
Chebi:135741
Chembl:2107067
Synonyms:TU; Testosterone undecylate; Testosterone 17β-undecanoate; ORG-538; CLR-610
Iupac Name:[(8''R'',9''S'',10''R'',13''S'',14''S'',17''S'')-10,13-Dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[''a'']phenanthren-17-yl] undecanoate
C:30
H:48
O:3
Smiles:CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
Stdinchi:1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
Stdinchikey:UDSFVOAUHKGBEK-CNQKSJKFSA-N

Testosterone undecanoate, sold under the brand name Nebido among others, is an androgen and anabolic steroid (AAS) medication that is used mainly in the treatment of low testosterone levels in men,[6] [5] [7] [8] [9] [10] [11] It is taken by mouth or given by injection into muscle.[12]

Side effects of testosterone undecanoate include symptoms of masculinization like acne, increased hair growth, voice changes, hypertension, elevated liver enzymes, hypertriglyceridemia, and increased sexual desire. The drug is a prodrug of testosterone, the biological ligand of the androgen receptor (AR) and hence is an androgen and anabolic steroid.[13] It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization and suitable for androgen replacement therapy. Testosterone undecanoate is a testosterone ester and a prodrug of testosterone in the body. Because of this, it is considered to be a natural and bioidentical form of testosterone.[14]

Testosterone undecanoate was introduced in China for use by injection and in the European Union for use by mouth in the 1970s. It became available for use by injection in the European Union in the early to mid 2000s and in the United States in 2014. Formulations for use by mouth are approved in the United States.[15] [16] Along with testosterone enanthate, testosterone cypionate, and testosterone propionate, testosterone undecanoate is one of the most widely used testosterone esters. However, it has advantages over other testosterone esters in that it can be taken by mouth and in that it has a far longer duration when given by injection.[17] In addition to its medical use, testosterone undecanoate is used to improve physique and performance. The drug is a controlled substance in many countries.

Oral administration of testosterone undecanoate is an effective method to achieve therapeutic physiological levels of serum testosterone in patients with hypogonadism. In addition, oral therapy has been found to have a positive impact in these patients on quality of life factors such as sexual function, mood, and mental status, as documented in various studies.[18]

Medical uses

Testosterone undecanoate is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Side effects

Side effects of testosterone undecanoate include virilization among others.

Anaphylaxis

The Reandron 1000 formulation (Aveed in the United States) contains 1,000 mg of testosterone undecanoate suspended in 4 ml castor oil with benzyl benzoate for solubilization and as a preservative, and is administered by intramuscular injection. As an excipient in Reandron 1000, benzyl benzoate has been reported as a cause of anaphylaxis (a serious life-threatening allergic reaction) in a case in Australia.[19] Bayer includes this report in information for health professionals and recommends that physicians "should be aware of the potential for serious allergic reactions" to preparations of this type.[20] In Australia, reports to the Adverse Drug Reactions Advisory Committee (ADRAC), which evaluates reports of adverse drug reactions for the Therapeutic Goods Administration (TGA), show several reports of allergic reactions since the anaphylaxis case from 2011.

Pharmacology

Pharmacodynamics

Testosterone undecanoate is a prodrug of testosterone and is an androgen and anabolic–androgenic steroid (AAS). That is, it is an agonist of the androgen receptor (AR).

Pharmacokinetics

Testosterone undecanoate has a very long elimination half-life and mean residence time when given as a depot intramuscular injection.[21] [22] Its elimination half-life is 20.9 days and its mean residence time is 34.9 days in tea seed oil, while its elimination half-life is 33.9 days and its mean residence time is 36.0 days in castor oil. These values are substantially longer than those of testosterone enanthate (which, in castor oil, has values of 4.5 days and 8.5 days, respectively).

Testosterone undecaondate has very low bioavailability when taken orally, only about 3-7% in men and 4-10% in women.[23] [24] [25] This bioavailability is increased with food, especially foods containing fat, thus it is typically recommended to be taken with a meal.[26] [27] [28] [29] It is absorbed through the lymphatic system (90-100%) and peak serum levels are reached after about 3-5 hours.[30] [31] From there, plasma levels decline, typically reaching pre-dose levels after 6-12 hours. The elimination half-life via the oral route has been stated to be 1.6 hours, with a mean residence time of 3.7 hours.[5] However, there is a large amount of individual variability in its duration of action.[32] For this reason it is often dosed twice or even three times a day.[32] [30]

Testosterone undecanoate is metabolized partially in the intestinal wall into 5-alpha-dihydrotestosterone undecanoate (DHTU).[33] In the blood, non-specific esterases metabolize testosterone undecanoate into testosterone and DHTU into dihydrotestosterone (DHT).[33] Thus, testosterone undecanoate increases plasma levels of both testerone and DHT. The fact the conversion happens in the blood complicates the accurate measurement of blood levels of testosterone induced by the drug, as the conversion continues to occur while blood samples are being prepared for assay. Ideally, enzyme inhibitors should be used to properly assay the blood testosterone levels induced by testosterone undecanoate.[33]

Chemistry

See also: Androgen ester and List of androgen esters.

Testosterone undecanoate, or testosterone 17β-undecanoate, is a synthetic androstane steroid and a derivative of testosterone.[34] [35] It is an androgen ester; specifically, it is the C17β undecylate (undecanoate) ester of testosterone. A related testosterone ester with a similarly very long duration is testosterone buciclate.

The first commercialized preparation of oral testosterone undecanoate had it dissolved in oleic acid.[32] This formulation had to be refrigerated in the pharmacy for reasons of stability and would only last about three months at room temperature.[32] A newer more stable pharmaceutical formulation with castor oil and propylene glycol laurate has since been developed.[32] This new formulation can be stored at room temperature for three years.[32] A novel self-emulsifying formulation of oral testosterone undecanoate in 300-mg capsules for use once per day has been under development.<[36]

History

In the late 1970s, testosterone undecanoate was introduced for oral use in Europe,[37] although intramuscular testosterone undecanoate had already been in use in China for several years.[38] Intramuscular testosterone undecanoate was not introduced in Europe and the United States until much later, in the early to mid 2000s and 2014, respectively.[39] [40] Testosterone undecanoate was approved in the United States only in 2014 after three previous rejections due to safety concerns.[41]

Society and culture

Generic names

Testosterone undecanoate is the generic name of the drug and its and .[42] [43] It is also referred to as testosterone undecylate.

Brand names

Testosterone undecanoate is or has been marketed under a variety of brand names, including Andriol, Androxon, Aveed, Cernos Depot, Jatenzo, Kyzatrex, Nebido, Nebido-R, Panteston, Reandron 1000, Restandol, Sustanon 250, Undecanoate 250, and Undestor.[44]

Availability

See also: List of androgens/anabolic steroids available in the United States. Oral testosterone undecanoate is available in Europe, Mexico, Asia, and the United States.[45]

Intramuscular testosterone undecanoate has been approved worldwide, including the European Union, Russia, and the United States.[46] [47] Intramuscular testosterone undecanoate is marketed as Nebido in Europe and as Aveed in the United States while oral testosterone undecanoate is marketed as Andriol.

Legal status

Testosterone undecanoate, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act.[48] [49]

In March 2019, the US Food and Drug Administration approved testosterone undecanoate (Jatenzo), an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland. The FDA granted the approval of Jatenzo to Clarus Therapeutics.[50]

In March 2022, testosterone undecanoate (Tlando) was approved for medical use in the United States.[51]

In July 2022, Kyzatrex, an oral testosterone undecanoate capsule, was approved for medical use in the United States. The FDA granted the approval of Kyzatrex to Marius Pharmaceuticals.[52] [53]

Research

Non-alcoholic steatohepatitis

In 2013, a phase II clinical trial testing intramuscular testosterone undecanoate for the treatment of non-alcoholic steatohepatitis (NASH) was initiated in the United Kingdom.[54] In the United States in 2018, Lipocine Inc. began investigating the potential of using an oral testosterone undecanoate formulation, known as LPCN-1144, in patients with NASH.[55]

Osteoporosis

In 2013, a study aimed to evaluate the efficacy of testosterone undecanoate therapy on bone mineral density (BMD) and biochemical markers of bone turnover in elderly males with osteoporosis and low serum testosterone levels.

They study found that administering low-dose testosterone undecanoate (TU) at a rate of 20 mg per day to elderly men with low serum testosterone and osteoporosis effectively increases bone mineral density in the lumbar spine and femoral neck, and improves bone turnover, similar to the standard-dose TU (40 mg, per day) treatment. The treatment did not exhibit any adverse side effects on the prostate gland, including prostate-specific antigen. Therefore, low-dose TU appears to be a safe and cost-effective protocol for treating elderly male osteoporosis.[56] However, further clinical trials with larger sample sizes, multiple centers, and long-term follow-ups are required to determine the efficacy and safety of low-dose testosterone undecanoate treatment in elderly male osteoporosis with low serum testosterone.

Health implications

Risks associated with treatment of late-onset hypogonadism

There is a potential concern in the medical community that the administration of testosterone therapy for the treatment of late-onset hypogonadism may escalate the risks associated with benign prostatic hyperplasia, prostate cancer and heart diseases.[57]

Body composition

In 2020, a study that evaluated the effects of testosterone therapy in men with testosterone deficiency and varying degrees of weight (normal weight, overweight, and obesity) on anthropometric and metabolic parameters found that long-term testosterone undecanoate therapy in hypogonadal men, regardless of their weight at the start of the study, led to improvements in several body composition parameters, including body weight, waist circumference, and body mass index. Additionally, testosterone undecanoate therapy was found to lower fasting blood glucose and HbA1c levels and improve lipid profiles in this population.[58]

Bone density

There have been several studies that evaluate the effect of testosterone therapy on bone density or bone mineral density (BMD). One study concluded that long-term testosterone replacement therapy (TRT) in middle-aged men with late-onset hypogonadism (LOH) and metabolic syndrome (MS) led to a significant increase in both vertebral and femoral bone mineral density (BMD) after 36 months of treatment, as measured by dual-energy x-ray absorptiometry. The TRT treatment was shown to induce a 5% per year increase in BMD without changes in body mass index (BMI). The study suggests that long-term TRT could be beneficial for improving bone health in middle-aged men with LOH and MS, even in the absence of osteoporosis.[59]

Notes and References

  1. Web site: Testosterone Use During Pregnancy . Drugs.com . 20 August 2019 . 18 March 2020 . 1 February 2014 . https://web.archive.org/web/20140201201902/http://www.drugs.com/pregnancy/testosterone.html . live .
  2. Web site: Anabolic steroid misuse . nhs.uk . 2022-11-04 . 2024-07-12.
  3. Web site: Kyzatrex- testosterone undecanoate capsule, liquid filled . DailyMed . 18 October 2022 . 21 January 2023 . 21 January 2023 . https://web.archive.org/web/20230121062449/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971 . live .
  4. Web site: Anabolic steroid misuse . nhs.uk . 2022-11-04 . 2024-07-12.
  5. Book: Nieschlag E, Behre HM, Nieschlag S . Andrology: Male Reproductive Health and Dysfunction. 13 January 2010. Springer Science & Business Media. 978-3-540-78355-8. 441–446.
  6. Book: Nieschlag E, Behre HM, Nieschlag S. Testosterone: Action, Deficiency, Substitution. 26 July 2012. Cambridge University Press. 978-1-107-01290-5. 313–315, 321–322. 3 January 2018. 7 April 2022. https://web.archive.org/web/20220407103354/https://books.google.com/books?id=MkrAPaQ4wJkC&pg=PA315. live.
  7. Book: Becker KL. Principles and Practice of Endocrinology and Metabolism. 2001. Lippincott Williams & Wilkins. 978-0-7817-1750-2. 1185–. 3 January 2018. 17 May 2020. https://web.archive.org/web/20200517043226/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1185. live.
  8. Book: Llewellyn W. Anabolics. 2011. Molecular Nutrition LLC. 978-0-9828280-1-4. 180–182, 331–334. 3 January 2018. 3 July 2022. https://web.archive.org/web/20220703055937/https://books.google.com/books?id=afKLA-6wW0oC&pg=PT180. live.
  9. Irwig MS . Testosterone therapy for transgender men . The Lancet. Diabetes & Endocrinology . 5 . 4 . 301–311 . April 2017 . 27084565 . 10.1016/S2213-8587(16)00036-X .
  10. Jacobeit JW, Gooren LJ, Schulte HM . Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals . The Journal of Sexual Medicine . 4 . 5 . 1479–1484 . September 2007 . 17635694 . 10.1111/j.1743-6109.2007.00556.x .
  11. Jacobeit JW, Gooren LJ, Schulte HM . Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals . European Journal of Endocrinology . 161 . 5 . 795–798 . November 2009 . 19749027 . 10.1530/EJE-09-0412 . free .
  12. Book: Bertelloni S, Hiort O. New Concepts for Human Disorders of Sexual Development. 28 September 2010. S. Karger AG. 978-3-8055-9569-8. 256–. 3 November 2016. 8 November 2020. https://web.archive.org/web/20201108083958/https://books.google.com/books?id=CQhaAgAAQBAJ&pg=PA256. live.
  13. Kicman AT . Pharmacology of anabolic steroids . British Journal of Pharmacology . 154 . 3 . 502–521 . June 2008 . 18500378 . 2439524 . 10.1038/bjp.2008.165 .
  14. Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV . Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement . The Journal of Clinical Endocrinology and Metabolism . 101 . 4 . 1318–1343 . April 2016 . 27032319 . 10.1210/jc.2016-1271 . free .
  15. Web site: Jatenzo- testosterone undecanoate capsule, liquid filled . DailyMed . 11 January 2021 . 27 May 2022 . 5 January 2022 . https://web.archive.org/web/20220105204904/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60 . live .
  16. Meyer L . FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism . U.S. Food and Drug Administration (FDA) . 27 August 2020 . 27 March 2019 . 45 . 7 September 2020 . https://web.archive.org/web/20200907133655/https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-testosterone-capsule-treatment-men-certain-forms-hypogonadism . live .
  17. Köhn FM, Schill WB . A new oral testosterone undecanoate formulation . World Journal of Urology . 21 . 5 . 311–315 . November 2003 . 14579074 . 10.1007/s00345-003-0372-x . 23627346 .
  18. Ahmad SW, Molfetto G, Montoya D, Camero A . Is Oral Testosterone the New Frontier of Testosterone Replacement Therapy? . Cureus . 14 . 8 . e27796 . August 2022 . 36106278 . 9452423 . 10.7759/cureus.27796 . free .
  19. Ong GS, Somerville CP, Jones TW, Walsh JP . Anaphylaxis triggered by benzyl benzoate in a preparation of depot testosterone undecanoate . Case Reports in Medicine . 2012 . 384054 . 2012 . 22272209 . 3261473 . 10.1155/2012/384054 . 384054 . free .
  20. Web site: Nebido Monograph  - Information for Health Care Professionals. 2016. 19 October 2016. Bayer. 19 October 2016. https://web.archive.org/web/20161019155919/http://www.nebido.com/en/hcp/product-information/nebido-monograph/index.php. live.
  21. Book: Payne AH, Hardy MP. The Leydig Cell in Health and Disease. 28 October 2007. Springer Science & Business Media. 978-1-59745-453-7. 423–. 6 October 2016. 10 November 2020. https://web.archive.org/web/20201110065252/https://books.google.com/books?id=x4ttqKIAOg0C&pg=PA423. live.
  22. Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E . Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies . European Journal of Endocrinology . 140 . 5 . 414–419 . May 1999 . 10229906 . 10.1530/eje.0.1400414 . 10.1.1.503.1752 . 22597244 .
  23. Täuber U, Schröder K, Düsterberg B, Matthes H . Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone . European Journal of Drug Metabolism and Pharmacokinetics . 11 . 2 . 145–149 . 1986 . 3770015 . 10.1007/BF03189840 . 32305408 .
  24. Book: Lemke TL, Williams DA . Foye's Principles of Medicinal Chemistry . 24 January 2012 . Lippincott Williams & Wilkins . 978-1-60913-345-0 . 1360– .
  25. Täuber U, Schröder K, Düsterberg B, Matthes H . Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone . European Journal of Drug Metabolism and Pharmacokinetics . 11 . 2 . 145–149 . April 1986 . 3770015 . 10.1007/BF03189840 .
  26. Book: Behre HM, Nieschlag E, Nieschlag S . Testosterone preparations for clinical use in males. Nieschlag E, Behre HM, Nieschlag S . 309–335. 10.1017/CBO9781139003353.016. Testosterone: Action, Deficiency, Substitution. 26 July 2012. Cambridge University Press. 978-1-107-01290-5.
  27. Book: Hohl A . Testosterone: From Basic to Clinical Aspects. 30 March 2017. Springer. 978-3-319-46086-4. 13–.
  28. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS . Important effect of food on the bioavailability of oral testosterone undecanoate . Pharmacotherapy . 23 . 3 . 319–325 . March 2003 . 12627930 . 10.1592/phco.23.3.319.32104 . 24440953 .
  29. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB . The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps . Clinical Endocrinology . 66 . 4 . 579–585 . April 2007 . 17371478 . 1859980 . 10.1111/j.1365-2265.2007.02781.x .
  30. Roth MY, Dudley RE, Hull L, Leung A, Christenson P, Wang C, Swerdloff R, Amory JK . Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride . International Journal of Andrology . 34 . 6 Pt 1 . 541–547 . December 2011 . 20969601 . 10.1111/j.1365-2605.2010.01120.x . 4269219 .
  31. Yin AY, Htun M, Swerdloff RS, Diaz-Arjonilla M, Dudley RE, Faulkner S, Bross R, Leung A, Baravarian S, Hull L, Longstreth JA, Kulback S, Flippo G, Wang C . Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation . Journal of Andrology . 33 . 2 . 190–201 . 4 March 2012 . 21474786 . 10.2164/jandrol.111.013169 . 4168025 .
  32. Behre HM, Wang C, Handelsman DJ, Nieschlag E . Pharmacology of testosterone preparations . Testosterone . 1 January 2001 . 405–444 . 10.1017/CBO9780511545221.015.
  33. Lachance S, Dhingra O, Bernstein J, Gagnon S, Savard C, Pelletier N, Boudreau N, Lévesque A . Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials . Future Science OA . 1 . 4 . FSO55 . November 2015 . 28031910 . 10.4155/fso.15.55 .
  34. Book: Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 641–642. 6 October 2016. 22 October 2020. https://web.archive.org/web/20201022172120/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA641. live.
  35. Book: Index Nominum 2000: International Drug Directory. January 2000. Taylor & Francis. 978-3-88763-075-1. 1002–1004. 13 December 2017. 25 January 2020. https://web.archive.org/web/20200125043731/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1002. live.
  36. Book: Byrne MM, Nieschlag E . Reference Module in Neuroscience and Biobehavioral Psychology. Androgens: Pharmacological Use and Abuse ☆. 2017. Elsevier . 10.1016/B978-0-12-809324-5.03356-3. 9780128093245.
  37. Book: Hoberman J . Testosterone Dreams: Rejuvenation, Aphrodisia, Doping . registration . 21 February 2005 . University of California Press. 978-0-520-93978-3. 134–.
  38. Book: Mundy AR, Fitzpatrick J, Neal DE, George NJ. The Scientific Basis of Urology. 26 July 2010. CRC Press. 978-1-84184-749-8. 294–. 27 October 2017. 14 April 2019. https://web.archive.org/web/20190414215011/https://books.google.com/books?id=h6HSBQAAQBAJ&pg=PA294. live.
  39. Book: Melmed S, Polonsky KS, Larsen PR, Kronenberg MH. Williams Textbook of Endocrinology. 11 November 2015. Elsevier Health Sciences. 978-0-323-34157-8. 709, 711, 765. 27 October 2017. 14 April 2019. https://web.archive.org/web/20190414214954/https://books.google.com/books?id=iPIACwAAQBAJ&pg=PA709. live.
  40. Testosterone Undecanoate-Schering AG . Drugs in R&D . 5 . 6 . 368–369 . 2004 . 15563244 . 10.2165/00126839-200405060-00012 . 43349541 .
  41. Web site: Tucker ME. FDA Approves Aveed Testosterone Jab, with Restrictions. Medscape. 13 December 2016. 7 March 2014. 1 February 2017. https://web.archive.org/web/20170201230413/http://www.medscape.com/viewarticle/821632. live.
  42. Book: Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012. Springer Science & Business Media. 978-94-011-4439-1. 6 October 2016. 19 August 2020. https://web.archive.org/web/20200819233400/https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA270. live.
  43. Web site: Testosterone . Drugs.com . 27 October 2017 . 13 November 2016 . https://web.archive.org/web/20161113175707/https://www.drugs.com/international/testosterone.html . live .
  44. Web site: Testosterone undecanoate profile and most popular brands in USA. 6 September 2020. Downsizefitness.com. 3 July 2022. https://web.archive.org/web/20220703055939/http://downsizefitness.com/rankings/testosterone-undecanoate/. live.
  45. Book: Arnold AP, Pfaff DW, Etgen AM, Fahrbach SE, Rubin RT. Hormones, Brain and Behavior, Five-Volume Set. 10 June 2002. Academic Press. 978-0-12-532104-4. 20–. 27 October 2017. 22 November 2020. https://web.archive.org/web/20201122130644/https://books.google.com/books?id=cGbE2nC__Q0C&pg=PA20. live.
  46. Book: Nieschlag E, Nieschlag S . The History of Testosterone and the Testes: From Antiquity to Modern Times . Testosterone . 2017 . 1–19 . Springer . 10.1007/978-3-319-46086-4_1 . 978-3-319-46084-0.
  47. Web site: Drug Product Database . Health Canada . 13 November 2016 . live . https://web.archive.org/web/20161119200516/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php . 19 November 2016 . 18 March 2010 .
  48. Book: Karch SB. Drug Abuse Handbook, Second Edition. 21 December 2006. CRC Press. 978-1-4200-0346-8. 30–. 11 November 2017. 14 April 2019. https://web.archive.org/web/20190414215105/https://books.google.com/books?id=ZjrMBQAAQBAJ&pg=PA30. live.
  49. Book: Lilley LL, Snyder JS, Collins SR. Pharmacology for Canadian Health Care Practice. 5 August 2016. Elsevier Health Sciences. 978-1-77172-066-3. 50. 11 November 2017. 14 April 2019. https://web.archive.org/web/20190414214954/https://books.google.com/books?id=dNgoDwAAQBAJ&pg=PA50. live.
  50. Web site: Clarus Therapeutics Receives U.S. FDA Approval of Jatenzo (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men. Clarustherapeutics.com. 14 March 2022. 19 February 2020. https://web.archive.org/web/20200219030921/http://www.clarustherapeutics.com/content/investors-and-media/releases/clarus-receives-fda-approval-of-jatenzo.htm. live.
  51. Web site: Tlando- testosterone undecanoate capsule, liquid filled . DailyMed . 28 March 2022 . 27 May 2022 . 3 July 2022 . https://web.archive.org/web/20220703055940/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=479b55bd-2023-486a-8922-3b1de48b935c . live .
  52. Web site: Drug Approval Package: Kyzatrex Capsules . accessdata.fda.gov . 21 December 2022 . 18 May 2024.
  53. Web site: Kyzatrex (testosterone undecanoate) FDA Approval History . 6 April 2023 . Drugs.com . 6 April 2023 . https://web.archive.org/web/20230406163529/https://www.drugs.com/history/kyzatrex.html . live .
  54. Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis. 25 April 2017. 14 March 2022. Clinicaltrials.gov. 9 April 2021. https://web.archive.org/web/20210409174402/https://clinicaltrials.gov/ct2/show/NCT01919294. live.
  55. Web site: Lipocine Inc. - Clinical Trials. Lipocine.com. 14 March 2022. 24 May 2019. https://web.archive.org/web/20190524084410/https://www.lipocine.com/pipeline/lpcn-1144/clinical-trials.htm. live.
  56. Wang YJ, Zhan JK, Huang W, Wang Y, Liu Y, Wang S, Tan P, Tang ZY, Liu YS . Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone . International Journal of Endocrinology . 2013 . 570413 . 2013 . 23533404 . 3603196 . 10.1155/2013/570413 . free .
  57. Snyder P . Testosterone treatment of late-onset hypogonadism - benefits and risks . Rev Endocr Metab Disord . 23 . 6 . 1151–1157 . December 2022 . 35266057 . 10.1007/s11154-022-09712-1.
  58. Saad F, Doros G, Haider KS, Haider A . Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study . International Journal of Obesity . 44 . 6 . 1264–1278 . June 2020 . 32060355 . 10.1038/s41366-019-0517-7 . 211102413 . 7260126 .
  59. Aversa A, Bruzziches R, Francomano D, Greco EA, Fornari R, Di Luigi L, Lenzi A, Migliaccio S . Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study . The Aging Male . 15 . 2 . 96–102 . June 2012 . 22439807 . 10.3109/13685538.2011.631230 . 6594250 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Testosterone undecanoate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.